TG Therapeutics Q4 2023 Adj EPS $(0.09) Beats $(0.10) Estimate, Sales $43.97M Beat $40.06M Estimate
Portfolio Pulse from Benzinga Newsdesk
TG Therapeutics (NASDAQ:TGTX) reported Q4 2023 adjusted EPS of $(0.09), surpassing the $(0.10) estimate, with sales of $43.97M exceeding the $40.06M forecast. This represents a significant increase from $80.00 thousand in sales during the same period last year.
February 28, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TG Therapeutics reported a Q4 2023 adjusted EPS of $(0.09), beating estimates, and sales of $43.97M, also above expectations. This indicates a significant year-over-year growth.
Beating both EPS and sales estimates typically generates positive investor sentiment, potentially leading to a short-term increase in stock price. The significant year-over-year sales growth further underscores the company's strong performance and may attract more investor interest.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100